Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 33-Iodobenzylguanidine 3Magnetic Resonance Spectroscopy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1olaparib 1fludarabine phosphate 1copper dotatate CU-64 1cabozantinib 1atezolizumab 1Specimen Handling 1Lutetium-177 1Lutetium 1Iodine-131 1Interleukin-13 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Cyclophosphamide 1Biopsy 190Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × Iodine-131 × NET × Clear all
NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡